📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-13 13:59
8 analysed today
FollowTelegram
8
Today
149,959
All-time analysed
42,990
Positive
6,669
Negative
91,590
Neutral
8,642
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
4 announcements match the current filters (relevance ≥ 5).
Rs 2.05 Cr PAT: Denis Chem Lab Reports 17% YoY Profit Decline in Q1 FY27
Denis Chem Lab reported a marginal 1.6% YoY revenue growth to Rs 43.99 Cr for the quarter ended June 30, 2026. Net profit declined by 17.3% YoY to Rs 2.05 Cr, down from Rs 2.48 Cr in the year-ago period, primarily due to higher raw material consumption costs. However, on a sequential basis, PAT recovered significantly from the low base of Rs 0.40 Cr in Q4 FY26. The company continues to operate in a single segment of transfusion solutions with limited pricing power due to regulatory controls.
Confidence: HIGH
What changedThe company has transitioned into the new financial year with stable revenue but compressed margins compared to the previous year's first quarter.
Why it mattersAs a micro-cap pharmaceutical player with a market cap of Rs 95 Cr, Denis Chem Lab's profitability is sensitive to raw material price fluctuations and its ability to operate at near-full capacity (95%).
Revenue (Q1 FY27): Rs 43.99 CrNet Profit (Q1 FY27): Rs 2.05 CrYoY PAT Growth: -17.3%QoQ PAT Growth: +412.5%Raw Material Cost to Revenue: 54.2%
📅 Short termThe stock may see neutral to slightly cautious sentiment due to the YoY profit decline, though the sharp QoQ recovery provides some support.
📈 Long termLong-term growth is constrained by current 95% capacity utilization; structural upside depends on the successful execution of the targeted 20-25% growth strategy through expansion.
⚠ Risk flags
- Limited pricing power due to DPCO and NPPA regulations
- High logistics expenses impacting regional competitiveness
- Intense competition from regional players
Key Highlights
Revenue from operations stood at Rs 43.99 Cr, a slight increase from Rs 43.28 Cr in Q1 FY26.
Net Profit for the quarter was Rs 2.05 Cr, representing a 17.3% decline compared to Rs 2.48 Cr YoY.
Cost of materials consumed rose to Rs 23.83 Cr, accounting for 54.2% of total revenue.
Earnings Per Share (EPS) decreased to Rs 1.47 from Rs 1.78 in the corresponding quarter of the previous year.
Finance costs reduced significantly to Rs 10.79 lakh from Rs 18.55 lakh YoY, reflecting lower debt servicing needs.
👀 What to Watch
Investors should monitor the company's progress on its planned capacity expansion, as current utilization is near 95%. Key focus areas include the management's ability to maintain margins despite high logistics costs and DPCO price restrictions on essential IVF products.
Rs 2.05 Cr PAT: Denis Chem Lab Reports 17% YoY Profit Decline in Q1 FY27
Denis Chem Lab reported a flat performance for Q1 FY27 with revenue from operations at Rs 43.99 Cr, a marginal 1.6% increase YoY. Net profit declined by 17.3% YoY to Rs 2.05 Cr from Rs 2.48 Cr, although it showed a significant recovery from the exceptionally low Rs 0.40 Cr reported in the preceding March 2026 quarter. The company continues to face margin pressure with material costs rising to Rs 23.83 Cr. Finance costs saw a healthy reduction of 41.8% YoY to Rs 0.11 Cr, reflecting a strong balance sheet with minimal debt.
Confidence: HIGH
What changedThe company reported its first-quarter results for FY27, showing a recovery in profitability compared to the previous quarter but a decline compared to the same period last year.
Why it mattersAs a micro-cap player in the competitive IVF segment, the company's ability to maintain margins despite high logistics and raw material costs is critical for its valuation.
Revenue (Q1 FY27): Rs 43.99 CrNet Profit (Q1 FY27): Rs 2.05 CrYoY Revenue Growth: 1.6%YoY PAT Growth: -17.3%Finance Cost: Rs 0.11 Cr
📅 Short termThe stock may remain range-bound as the results show stagnant top-line growth and a YoY decline in earnings.
📈 Long termLong-term growth is dependent on the company's ability to expand capacity and penetrate deeper into rural and defense institutional sectors.
⚠ Risk flags
- High raw material cost sensitivity
- Limited pricing power due to DPCO regulations
- High logistics expenses for centralized manufacturing
Key Highlights
Revenue from operations remained stagnant at Rs 43.99 Cr vs Rs 43.28 Cr in the year-ago period.
Net Profit stood at Rs 2.05 Cr, down 17.3% YoY but up significantly from Rs 0.40 Cr in Q4 FY26.
Finance costs reduced to Rs 0.11 Cr from Rs 0.19 Cr in June 2025, a 41.8% decrease.
Cost of materials consumed increased to Rs 23.83 Cr, representing 54% of revenue.
Earnings Per Share (EPS) for the quarter was Rs 1.47, down from Rs 1.78 YoY.
👀 What to Watch
Watch for updates on the company's planned capacity expansion, as current utilization is near 95%, and monitor the impact of DPCO price controls on margins.
Denis Chem Lab Sets Sept 18 as Record Date for Dividend; Re-appoints MD for 3 Years
Denis Chem Lab has fixed September 18, 2026, as the record date for its final dividend for FY 2025-26. The Board has also re-appointed Dr. Himanshu C. Patel as Managing Director for a three-year term effective August 1, 2026, ensuring leadership continuity. These proposals, along with the appointment of a new secretarial auditor for a five-year term, are subject to shareholder approval at the 45th AGM on September 25, 2026. The company currently operates at a high capacity utilization of 95%, with TTM revenue of Rs 182 Cr.
Confidence: HIGH
What changedThe company has established the timeline for its annual dividend payout and confirmed the extension of the current Managing Director's tenure.
Why it mattersLeadership continuity is critical as the company seeks to expand capacity to grow beyond its current Rs 182 Cr revenue base. The dividend provides a yield signal for a stock currently trading at a P/E of 11.7.
Record Date: September 18, 2026AGM Date: September 25, 2026MD Tenure Extension: 3 yearsCapacity Utilization: 95%TTM Revenue: Rs 182 Cr
📅 Short termThe stock may see routine price adjustments around the ex-dividend date and record date (Sept 18).
📈 Long termManagement continuity is positive for long-term strategy; however, structural growth depends on overcoming high logistics costs and DPCO price controls mentioned in the company profile.
⚠ Risk flags
- Limited pricing power due to DPCO price controls
- High logistics expenses impacting regional competitiveness
Key Highlights
Record date for final dividend for FY 2025-26 fixed as September 18, 2026
45th Annual General Meeting (AGM) scheduled for September 25, 2026
Managing Director Dr. Himanshu C. Patel re-appointed for a 3-year term starting August 1, 2026
Secretarial Auditor appointed for a 5-year term covering FY 2026-27 to 2030-31
Remote e-voting period set from September 22 to September 24, 2026
👀 What to Watch
Investors should monitor the AGM outcome for the specific dividend quantum and management commentary on the execution timeline for planned capacity expansions, given the current 95% utilization.
3-Year Re-appointment of MD and Record Date for Dividend Fixed for Sept 18
Denis Chem Lab has re-appointed Dr. Himanshu C. Patel as Managing Director for a three-year term effective August 1, 2026, ensuring leadership continuity. The company has fixed September 18, 2026, as the record date for the final dividend of FY 2025-26, with the 45th AGM scheduled for September 25, 2026. Additionally, a new Secretarial Auditor has been appointed for a five-year block (FY27-FY31). These administrative steps follow a year where the company achieved TTM revenues of Rs 182 Cr, slightly exceeding its previous guidance of Rs 170-175 Cr.
Confidence: HIGH
What changedThe company has formalized the extension of its Managing Director's tenure and set the timeline for its annual shareholder meeting and dividend payout.
Why it mattersLeadership stability is critical as the company seeks to maintain its 10% operating margins and navigate high logistics costs in the competitive intravenous fluids (IVF) market.
MD Re-appointment Term: 3 yearsSecretarial Auditor Term: 5 yearsRecord Date: September 18, 2026AGM Date: September 25, 2026TTM Revenue: Rs 182 Cr
📅 Short termThe stock may witness routine price adjustments around the dividend record date of September 18.
📈 Long termLeadership continuity supports the company's long-term strategy of rural market penetration and leveraging its 110+ product licenses.
⚠ Risk flags
- Related-party relationships among directors (Dr. Himanshu C. Patel, Ms. Anar H. Patel, and Mr. Dinesh B. Patel)
Key Highlights
Re-appointment of Dr. Himanshu C. Patel as Managing Director for a 3-year term starting August 1, 2026.
Record date for final dividend entitlement fixed as September 18, 2026.
45th Annual General Meeting (AGM) to be held on September 25, 2026.
Appointment of M/s. Kashyap R. Mehta & Partners as Secretarial Auditors for a 5-year term (FY 2026-27 to 2030-31).
Dr. Himanshu C. Patel brings over 40 years of experience in the medical and pharmaceutical fields.
👀 What to Watch
Monitor the upcoming AGM on September 25 for the formal approval of the dividend and updates on capacity expansion plans, as the company is currently operating at 95% utilization.
